Using blood methylomes to predict response to amisulpride in the first-episode psychosis in the OPTiMiSE cohort.

ABSTRACT: Treatment of schizophrenia relies heavily on the use of antipsychotic drugs. Their efficacy is at present determined by lengthy trial-and-error approach, calling for more efficient strategies based on personalized medicine. Here, we present a prospective study of 116 first-episode-psychosis (FEP) patients from the OPTiMiSE cohort, aiming to identify blood epigenomic biomarkers predicting response to amisulpride and to shed light on involved mechanisms by linking the observed methylation patterns to genetic variation and gene expression. The analysis of 210 paired (baseline and follow-up) blood methylomes revealed 67 regions stably differentially methylated between good and bad responders and 197 regions with response-specific dynamics. The former were primarily enriched in functions relate

SUBMITTER: Lokmer A 

PROVIDER: S-EPMC12501013 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature